Covalent Organic Framework (C
cancer
covalent triazine framework C6N6
density functional theory
drug delivery
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
22 Oct 2022
22 Oct 2022
Historique:
received:
28
09
2022
revised:
14
10
2022
accepted:
17
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Continuous studies are being carried out to explore new methods and carrier surfaces for target drug delivery. Herein, we report the covalent triazine framework C
Identifiants
pubmed: 36363017
pii: ma15217425
doi: 10.3390/ma15217425
pmc: PMC9654209
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Faisal University
ID : 1234
Références
Int J Nanomedicine. 2018 Oct 09;13:6143-6176
pubmed: 30349242
Eur J Cancer. 1998 Jan;34(1):162-7
pubmed: 9624252
Carbohydr Polym. 2018 Sep 1;195:453-459
pubmed: 29804999
Biochim Biophys Acta. 1990 Aug 13;1054(1):14-20
pubmed: 2200526
In Silico Pharmacol. 2021 Jan 11;9(1):12
pubmed: 33489711
RSC Adv. 2021 Feb 10;11(12):6958-6971
pubmed: 35423203
Pharmacol Rep. 2012;64(5):1020-37
pubmed: 23238461
Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:1440-1453
pubmed: 28482511
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
J Am Chem Soc. 2010 May 12;132(18):6498-506
pubmed: 20394428
ACS Nano. 2018 Apr 24;12(4):3886-3891
pubmed: 29648440
Biomedicine (Taipei). 2017 Dec;7(4):23
pubmed: 29130448
Am J Clin Pathol. 2004 Oct;122(4):598-609
pubmed: 15487459
Bioimpacts. 2019;9(1):5-13
pubmed: 30788255
Nanomaterials (Basel). 2017 Aug 29;7(9):
pubmed: 28850089
J Cancer Sci Ther. 2009 Dec 1;1(2):1-4
pubmed: 20740081
J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):97-102
pubmed: 10676988
Int J Biol Macromol. 2019 Oct 15;139:994-1001
pubmed: 31401278
Phys Chem Chem Phys. 2008 Nov 28;10(44):6615-20
pubmed: 18989472
Biochem Biophys Res Commun. 2015 Dec 18;468(3):419-27
pubmed: 26168726
Angew Chem Int Ed Engl. 2005 Oct 7;44(39):6358-62
pubmed: 16138384
Curr Med Chem. 2011;18(29):4538-56
pubmed: 21864282
Chem Rev. 1997 May 8;97(3):829-1014
pubmed: 11848890
J Chem Theory Comput. 2011 Mar 8;7(3):625-632
pubmed: 21516178
J Mater Chem B. 2018 Aug 7;6(29):4747-4755
pubmed: 32254302
Urol Oncol. 2000 Apr 1;5(3):93-96
pubmed: 10765014
Chem Rev. 2016 Feb 24;116(4):2602-63
pubmed: 26854975
J Phys Chem A. 2006 Mar 16;110(10):3349-51
pubmed: 16526611
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
J Phys Chem A. 2011 Nov 17;115(45):12983-90
pubmed: 21786796
J Control Release. 2001 Jul 6;74(1-3):295-302
pubmed: 11489509
J Chromatogr B Biomed Sci Appl. 1997 May 9;692(2):427-35
pubmed: 9188833
Adv Mater. 2015 Dec 2;27(45):7261-84
pubmed: 26459239
Lancet. 1995 Apr 15;345(8955):939-44
pubmed: 7715291
Science. 1990 Sep 28;249(4976):1527-33
pubmed: 2218494
Chem Eng Sci. 2015 Mar 24;125:75-84
pubmed: 25684779
Arch Toxicol. 2014 Jul;88(7):1391-417
pubmed: 24894431
Br J Cancer. 1996 Nov;74(10):1545-52
pubmed: 8932333
Anal Chim Acta. 2018 Dec 7;1036:121-132
pubmed: 30253822
Chem Commun (Camb). 2006 Mar 21;(11):1182-4
pubmed: 16518484
Clin Breast Cancer. 2003 Nov;4 Suppl 2:S76-83
pubmed: 14667278
Drug Resist Updat. 2005 Oct;8(5):298-310
pubmed: 16172017
Adv Mater. 2017 Feb;29(5):
pubmed: 27882622
Am J Clin Oncol. 2002 Feb;25(1):57-9
pubmed: 11823698
Biomacromolecules. 2011 Jul 11;12(7):2562-72
pubmed: 21598958
ACS Nano. 2009 Jan 27;3(1):16-20
pubmed: 19206243
J Phys Chem Lett. 2012 Jan 19;3(2):242-5
pubmed: 26698601
JAMA. 1976 May 10;235(19):2135-6
pubmed: 946546
J Control Release. 2010 Nov 1;147(3):314-25
pubmed: 20691738
J Mol Model. 2020 Sep 26;26(10):287
pubmed: 32980919
RSC Adv. 2020 Aug 27;10(53):31997-32010
pubmed: 35518175
Anticancer Drugs. 1999 Sep;10(8):767-76
pubmed: 10573209
Chem Rev. 2017 May 10;117(9):6225-6331
pubmed: 28306244
Adv Mater. 2018 Apr;30(16):e1707389
pubmed: 29537662